Skip to Content
Merck
CN

P0048

Pemoline

≥98% (HPLC)

Synonym(s):

2-Amino-5-phenyl4(5H)-oxazolone, Phenylisohydantoin

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C9H8N2O2
CAS Number:
2152-34-3
Molecular Weight:
176.17
NACRES:
NA.77
PubChem Substance ID:
329819998
UNSPSC Code:
12352200
EC Number:
218-438-8
MDL number:
MFCD00083197

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

NRNCYVBFPDDJNE-UHFFFAOYSA-N

InChI

1S/C9H8N2O2/c10-9-11-8(12)7(13-9)6-4-2-1-3-5-6/h1-5,7H,(H2,10,11,12)

SMILES string

NC1=NC(=O)C(O1)c2ccccc2

assay

≥98% (HPLC)

form

solid

drug control

USDEA Schedule IV; Home Office Schedule 4.2; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet, kontrollierte Droge in Deutschland

solubility

DMSO: 28 mg/mL

originator

Boehringer Ingelheim

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Pemoline is a CNS stimulant. Pemoline is used to treat attention-deficit hyperactivity disorder (ADHD). Pemoline is a Schedule IV drug and offers some advantages over other stimulants in that it does not reduce the appetite or cause dry mouth.
Pemoline is a CNS stimulant.

Features and Benefits

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges, type P3 (EN 143) respirator cartridges

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
029K4630

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vera Peuckmann et al.
The Cochrane database of systematic reviews, (11)(11), CD006788-CD006788 (2010-11-12)
In healthy individuals, fatigue is a protective response to physical or mental stress, often relieved by rest. By contrast, in palliative care patients fatigue can be severely debilitating, thereby impacting daily activity and quality of life, often with rest not
Philip Shaw et al.
The American journal of psychiatry, 166(1), 58-63 (2008-09-17)
While there has been considerable concern over possible adverse effects of psychostimulants on brain development, this issue has not been examined in a prospective study. The authors sought to determine prospectively whether psychostimulant treatment for attention deficit hyperactivity disorder (ADHD)
Mark Olfson et al.
The Journal of clinical psychiatry, 74(1), 43-50 (2013-02-20)
The authors investigated trends and patterns in stimulant treatment of adults visiting office-based medical practices in the United States. A time series analysis of data from the 1994 to 2009 National Ambulatory Medical Care Surveys (no. of visits = 372,702)
A M Muehlmann et al.
Journal of intellectual disability research : JIDR, 56(5), 490-500 (2011-10-13)
Self-injurious behaviour (SIB) is prevalent in neurodevelopmental disorders, but its expression is highly variable within, and between diagnostic categories. This raises questions about the factors that contribute to aetiology and expression of SIB. Expression of SIB is generally described in
Amber M Muehlmann et al.
Behavioural brain research, 189(1), 32-40 (2008-02-05)
Self-injurious behaviour (SIB) is exhibited by individuals with a broad variety of developmental disorders and genetic abnormalities, including autism and Lesch-Nyhan, Prader-Willi and Rett syndromes. Most research has focused on environmental factors that reinforce SIB, and less is known about
View All Related Papers

Articles

Dopamine Receptors

We offer many products related to dopamine receptors for your research needs.

多巴胺受体

我们可提供多种多巴胺受体相关的产品，满足您的各类研究需求。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service